Subcutaneously implanted central venous access devices in cancer patients: A prospective analysis

Roderich E. Schwarz, Jeffrey S. Groeger, Daniel G. Coit

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

BACKGROUND. Long term intravenous access is a common requirement for cancer patients. This analysis was designed to determine device-related morbidity and factors predictive of poor long term outcome for patients with subcutaneous single lumen intravenous access ports. METHODS. Six hundred eighty patients who underwent subcutaneous intravenous port placement between June 1987 and May 1989 at Memorial Sloan-Kettering Cancer Center were followed prospectively until port removal, death, or a maximum of 1960 days. Indications for and circumstances of placement, patient diagnoses, patient demographics, and subsequent courses of treatment were recorded, as well as technical and microbiologic device-related complications. Total, device specific, and complication free device durations were calculated. RESULTS. The median patient age was 52.4 years (range, 1.6-83.9 years). The female- to-male ratio was 1.5 to 1. Cancer diagnoses included solid organ tumors (84%), leukemia (4%), lymphoma (11%), and others (1%). Indications included access for systemic chemotherapy (98%), total parenteral nutrition (0.5%), and others (1.5%). One insertion complication and six insertion failures occurred, without mortality. The estimated mean overall actuarial device specific duration was 1191 days (range, 2-1960 days). Actuarial mean complication free, device specific duration was 952 days. Complications included sepsis (n = 31; 4.4%), site infection (n = 31; 4.4%), and accessibility failures such as thrombosis and leakage (n = 40, 5.7%). Reasons for end of port duration were patient death (72.4%), end of treatment (13.5%), functional failure or intractable infection (11.2%), and others (2.9%). Independent factors correlating with decreased port specific, complication free duration included placement site, age, tumor type, and catheter tip position. CONCLUSIONS. Subcutaneous intravenous access ports in cancer patients are safe and well tolerated. Long term device duration is primarily influenced by patient survival. In this study, 90% of patients alive at 1 year and 70% of patients alive at 4 years had a functional port.

Original languageEnglish (US)
Pages (from-to)1635-1640
Number of pages6
JournalCancer
Volume79
Issue number8
DOIs
StatePublished - Apr 15 1997

Fingerprint

Equipment and Supplies
Neoplasms
Total Parenteral Nutrition
Infection
Lymphoma
Sepsis
Leukemia
Thrombosis
Catheters
Demography
Morbidity
Drug Therapy
Survival
Mortality
Therapeutics

Keywords

  • cancer patient
  • device specific survival
  • intravenous access
  • intravenous port removal
  • line infection
  • subcutaneous ports
  • surgical access

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Subcutaneously implanted central venous access devices in cancer patients : A prospective analysis. / Schwarz, Roderich E.; Groeger, Jeffrey S.; Coit, Daniel G.

In: Cancer, Vol. 79, No. 8, 15.04.1997, p. 1635-1640.

Research output: Contribution to journalArticle

Schwarz, Roderich E. ; Groeger, Jeffrey S. ; Coit, Daniel G. / Subcutaneously implanted central venous access devices in cancer patients : A prospective analysis. In: Cancer. 1997 ; Vol. 79, No. 8. pp. 1635-1640.
@article{f66e3325985647e0ba1029b00527ca2f,
title = "Subcutaneously implanted central venous access devices in cancer patients: A prospective analysis",
abstract = "BACKGROUND. Long term intravenous access is a common requirement for cancer patients. This analysis was designed to determine device-related morbidity and factors predictive of poor long term outcome for patients with subcutaneous single lumen intravenous access ports. METHODS. Six hundred eighty patients who underwent subcutaneous intravenous port placement between June 1987 and May 1989 at Memorial Sloan-Kettering Cancer Center were followed prospectively until port removal, death, or a maximum of 1960 days. Indications for and circumstances of placement, patient diagnoses, patient demographics, and subsequent courses of treatment were recorded, as well as technical and microbiologic device-related complications. Total, device specific, and complication free device durations were calculated. RESULTS. The median patient age was 52.4 years (range, 1.6-83.9 years). The female- to-male ratio was 1.5 to 1. Cancer diagnoses included solid organ tumors (84{\%}), leukemia (4{\%}), lymphoma (11{\%}), and others (1{\%}). Indications included access for systemic chemotherapy (98{\%}), total parenteral nutrition (0.5{\%}), and others (1.5{\%}). One insertion complication and six insertion failures occurred, without mortality. The estimated mean overall actuarial device specific duration was 1191 days (range, 2-1960 days). Actuarial mean complication free, device specific duration was 952 days. Complications included sepsis (n = 31; 4.4{\%}), site infection (n = 31; 4.4{\%}), and accessibility failures such as thrombosis and leakage (n = 40, 5.7{\%}). Reasons for end of port duration were patient death (72.4{\%}), end of treatment (13.5{\%}), functional failure or intractable infection (11.2{\%}), and others (2.9{\%}). Independent factors correlating with decreased port specific, complication free duration included placement site, age, tumor type, and catheter tip position. CONCLUSIONS. Subcutaneous intravenous access ports in cancer patients are safe and well tolerated. Long term device duration is primarily influenced by patient survival. In this study, 90{\%} of patients alive at 1 year and 70{\%} of patients alive at 4 years had a functional port.",
keywords = "cancer patient, device specific survival, intravenous access, intravenous port removal, line infection, subcutaneous ports, surgical access",
author = "Schwarz, {Roderich E.} and Groeger, {Jeffrey S.} and Coit, {Daniel G.}",
year = "1997",
month = "4",
day = "15",
doi = "10.1002/(SICI)1097-0142(19970415)79:8<1635::AID-CNCR30>3.0.CO;2-X",
language = "English (US)",
volume = "79",
pages = "1635--1640",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Subcutaneously implanted central venous access devices in cancer patients

T2 - A prospective analysis

AU - Schwarz, Roderich E.

AU - Groeger, Jeffrey S.

AU - Coit, Daniel G.

PY - 1997/4/15

Y1 - 1997/4/15

N2 - BACKGROUND. Long term intravenous access is a common requirement for cancer patients. This analysis was designed to determine device-related morbidity and factors predictive of poor long term outcome for patients with subcutaneous single lumen intravenous access ports. METHODS. Six hundred eighty patients who underwent subcutaneous intravenous port placement between June 1987 and May 1989 at Memorial Sloan-Kettering Cancer Center were followed prospectively until port removal, death, or a maximum of 1960 days. Indications for and circumstances of placement, patient diagnoses, patient demographics, and subsequent courses of treatment were recorded, as well as technical and microbiologic device-related complications. Total, device specific, and complication free device durations were calculated. RESULTS. The median patient age was 52.4 years (range, 1.6-83.9 years). The female- to-male ratio was 1.5 to 1. Cancer diagnoses included solid organ tumors (84%), leukemia (4%), lymphoma (11%), and others (1%). Indications included access for systemic chemotherapy (98%), total parenteral nutrition (0.5%), and others (1.5%). One insertion complication and six insertion failures occurred, without mortality. The estimated mean overall actuarial device specific duration was 1191 days (range, 2-1960 days). Actuarial mean complication free, device specific duration was 952 days. Complications included sepsis (n = 31; 4.4%), site infection (n = 31; 4.4%), and accessibility failures such as thrombosis and leakage (n = 40, 5.7%). Reasons for end of port duration were patient death (72.4%), end of treatment (13.5%), functional failure or intractable infection (11.2%), and others (2.9%). Independent factors correlating with decreased port specific, complication free duration included placement site, age, tumor type, and catheter tip position. CONCLUSIONS. Subcutaneous intravenous access ports in cancer patients are safe and well tolerated. Long term device duration is primarily influenced by patient survival. In this study, 90% of patients alive at 1 year and 70% of patients alive at 4 years had a functional port.

AB - BACKGROUND. Long term intravenous access is a common requirement for cancer patients. This analysis was designed to determine device-related morbidity and factors predictive of poor long term outcome for patients with subcutaneous single lumen intravenous access ports. METHODS. Six hundred eighty patients who underwent subcutaneous intravenous port placement between June 1987 and May 1989 at Memorial Sloan-Kettering Cancer Center were followed prospectively until port removal, death, or a maximum of 1960 days. Indications for and circumstances of placement, patient diagnoses, patient demographics, and subsequent courses of treatment were recorded, as well as technical and microbiologic device-related complications. Total, device specific, and complication free device durations were calculated. RESULTS. The median patient age was 52.4 years (range, 1.6-83.9 years). The female- to-male ratio was 1.5 to 1. Cancer diagnoses included solid organ tumors (84%), leukemia (4%), lymphoma (11%), and others (1%). Indications included access for systemic chemotherapy (98%), total parenteral nutrition (0.5%), and others (1.5%). One insertion complication and six insertion failures occurred, without mortality. The estimated mean overall actuarial device specific duration was 1191 days (range, 2-1960 days). Actuarial mean complication free, device specific duration was 952 days. Complications included sepsis (n = 31; 4.4%), site infection (n = 31; 4.4%), and accessibility failures such as thrombosis and leakage (n = 40, 5.7%). Reasons for end of port duration were patient death (72.4%), end of treatment (13.5%), functional failure or intractable infection (11.2%), and others (2.9%). Independent factors correlating with decreased port specific, complication free duration included placement site, age, tumor type, and catheter tip position. CONCLUSIONS. Subcutaneous intravenous access ports in cancer patients are safe and well tolerated. Long term device duration is primarily influenced by patient survival. In this study, 90% of patients alive at 1 year and 70% of patients alive at 4 years had a functional port.

KW - cancer patient

KW - device specific survival

KW - intravenous access

KW - intravenous port removal

KW - line infection

KW - subcutaneous ports

KW - surgical access

UR - http://www.scopus.com/inward/record.url?scp=0030907865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030907865&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19970415)79:8<1635::AID-CNCR30>3.0.CO;2-X

DO - 10.1002/(SICI)1097-0142(19970415)79:8<1635::AID-CNCR30>3.0.CO;2-X

M3 - Article

C2 - 9118051

AN - SCOPUS:0030907865

VL - 79

SP - 1635

EP - 1640

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -